¼ÛÁ¤À± ¸íÀÇ

ÃÖ¼Ò ¹üÀ§ À¯¹æÁ¾¾ç ¼ö¼úÀÇ ´ë°¡

¼ÛÁ¤À± ¸íÀÇ

  • ¼Ò ¼Ó
    °­µ¿°æÈñ´ëÇб³º´¿ø À¯¹æ³»ºÐºñ¿Ü°ú
  • Àü¹®ºÐ¾ß
    À¯¹æ¾Ï, °©»ó¼±¾Ï, ºÎ°©»ó¼±, ºÎ½ÅÁúȯ, °©»ó¼± ·Îº¿¼ö¼ú

ÁÖ¿ä Áø·á ºÐ¾ß´Â À¯¹æ¾Ï, °©»ó¼±¾Ï, ºÎ½ÅÁúȯÀÌ´Ù. À¯¹æ¾Ï ´ÙÇÐÁ¦ÆÀÀ» ±¸¼ºÇϰí À¯ÀüÀÚ ºÐ¼®À» ÅëÇØ °¢°¢ÀÇ È¯ÀÚ¿¡°Ô °¡Àå ºü¸£°í ¿Ïº®ÇÑ Ä¡·á¸¦ Á¦°øÇϱâ À§ÇØ ³ë·ÂÇÏ´Â ÀÇ»ç´Ù. ´ë³»¿ÜÀûÀ¸·Î Ȱ¹ßÇÑ ¿¬±¸È°µ¿À» ÅëÇØ ±¹Á¦À¯¹æ¾Ï½ÉÆ÷Áö¿ò ¹× Çѱ¹À¯¹æ¾ÏÇÐȸ¿¡¼­ ÃÖ¿ì¼ö³í¹® Çмú»óÀ» ¼ö»óÇß´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • °æÈñ´ëÇб³ Àǰú´ëÇÐ ÀÇÇлç
  • °æÈñ´ëÇб³ Àǰú´ëÇÐ ÀÇÇм®»ç
  • °æÈñ´ëÇб³ Àǰú´ëÇÐ ÀÇÇйڻç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) °­µ¿°æÈñ´ëÇб³º´¿ø ¿Ü°ú ±³¼ö
  • °­µ¿°æÈñ´ëÇб³ÀǴ뺴¿ø ¿Ü°úÀå ¿ªÀÓ
  • °­µ¿°æÈñ´ëÇб³º´¿ø È«º¸¸¶ÄÉÆÃ¼¾ÅÍÀå ¿ªÀÓ
  • °­µ¿°æÈñ´ëÀǴ뺴¿ø ±¹Á¦±³·ù½Ç ºÎ½ÇÀå ¿ªÀÓ

¼ö»ó³»¿ª

Awards List
  • Çѱ¹À¯¹æ¾ÏÇÐȸ ÃÖ¿ì¼ö³í¹®»ó

ÇÐȸȰµ¿

Academic activities
  • 2023 ~ ÇöÀç´ëÇѿܰúÇÐȸ ÀÇ·á½É»çÀÌ»ç
  • 2022 ~ 2024´ëÇÑ ³»ºÐºñ¿Ü°úÇÐȸ °¨»ç
  • 2002 ~ ÇöÀçÇѱ¹À¯¹æ¾ÏÇÐȸ Æò»ýȸ¿ø
  • 2002 ~ ÇöÀç´ëÇѳ»ºÐºñ¿Ü°úÇÐȸ Æò»ýȸ¿ø
³»ºÐºñ¿Ü°úÇÐ
´ëÇ¥¼­Àû

³»ºÐºñ¿Ü°úÇÐ

  • ÀúÀÚ(±Û)´ëÇѰ©»ó¼±³»ºÐ¿Ü°úÇÐȸ
  • ÃâÆÇ»ç±ºÀÚÃâÆÇ»ç
  • ¹ßÇàÀÏ2018³â
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 2°Ç
Á¦ ¸ñ À¯¹æÇÐ
ÃâÆÇ»ç ÆäÀÌÁö¿ø ¹ßÇàÀÏ 2017³â
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 6°Ç
Á¦ ¸ñ An observational, prospective , open labe, multicenter study to evaluate the safety and effectiveness of Prefilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer.
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Breast
Á¦ ¸ñ Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö BREAST CANCER RESEARCH
Á¦ ¸ñ Label-free breast cancer detection using fiber probe-based Raman spectrochemical biomarker-dominated profiles extracted from a mixture analysis algorithm
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö Analytical Methods
Á¦ ¸ñ Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö BMC CANCER
Á¦ ¸ñ Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006)
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö Journal of Breast Cancer
Á¦ ¸ñ Clinical Significance of Receptor-Interacting Protein 3 and Parkin, Essential Molecules for Necroptosis, in Breast Cancer
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö Journal of Breast Cancer

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

* ¾ÏÁٱ⼼Æ÷ ¿¬±¸¸¦ ÅëÇÑ Áø´Ü°ú Ä¡·á
* À¯¹æ¾Ï ´ÙÇÐÁ¦ÆÀÀ» ±¸¼ºÇϰí À¯ÀüÀÚ ºÐ¼®À» ÅëÇØ °¢°¢ÀÇ È¯ÀÚ¿¡°Ô °¡Àå ºü¸£°í ¿Ïº®ÇÑ Ä¡·á¸¦ Á¦°øÇϱâ À§ÇØ ³ë·ÂÇÏ´Â ÀÇ»ç´Ù. ´ë³»¿ÜÀûÀ¸·Î Ȱ¹ßÇÑ ¿¬±¸È°µ¿À» ÅëÇØ ±¹Á¦À¯¹æ¾Ï½ÉÆ÷Áö¿ò ¹× Çѱ¹À¯¹æ¾ÏÇÐȸ¿¡¼­ ÃÖ¿ì¼ö³í¹® Çмú»óÀ» ¼ö»óÇß´Ù.

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

À¯¹æ°©»ó¼±Àº ¿Ü°úºÐ¾ß¿¡¼­ ¿©¼ºÀÌ ´ëºÎºÐ ÀÔ´Ï´Ù. ȯÀÚµéÀÇ ±Ã±ÝÁõ°ú Áú¹®À» ¸íÄèÇÏ°Ô ÇØ°áÇØ ÁÖ´Â °Í, ¸¶À½À» Çì¾Æ¸®´Â ÀμúÀ» ³õÄ¡Áö ¾Ê´Â °ÍÀ̶ó°í »ý°¢ÇÕ´Ï´Ù. ¾Æ¹«¸® ÁÁÀº ÀÇ·á ½Ã½ºÅÛ°ú ¼ú±â°¡ À־ ȯÀÚÀÇ ¸¶À½À» ¾î·ç¸¸Áö´Â °ÍÀ» Àؾ´Â ¾È µÈ´Ù´Â °Í. ¶ÇÇÑ 3ºÐ Áø·á´Â ¾ø´Ù¶ó´Â ¸¶À½À¸·Î ȯÀÚ¿Í Áö¼ÓÀûÀ¸·Î Ä¿¹Â´ÏÄÉÀ̼ÇÇÏ°í ¾ðÁ¦³ª Ä£ÀýÀ» ÀÒÁö ¾Ê°í Áø·á¸¦ º¸´Â°Ô ÃÖ°íÀÇ Ä¡·á¹ýÀ̶ó°í »ý°¢ÇÕ´Ï´Ù.

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°­µ¿°æÈñ´ëÇб³º´¿ø

Á¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1577-5800
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°­µ¿°æÈñ´ëÇб³º´¿øÀº Àǰú, ÇÑÀǰú, Ä¡°ú´ëÇÐÀ» ¸ðµÎ º¸À¯ÇÑ º´¿øÀ¸·Î, 3°³ ´ëÇк´¿øÀÇ ¼öÁØ ³ôÀº ÀÇ·á¼­ºñ½º¸¦ ÇÑ ¹ø¿¡ ¹ÞÀ» ¼ö ÀÖ´Ù. ¿¬¸éÀû 24,000¿© Æò º»°ü Áö»ó 14Ãþ, º°°ü Áö»ó 4ÃþÀÇ 800º´»óÀ» °®Ãè´Ù. ³úÁúȯ¡¤°üÀý¡¤Ã´Ãß µî Áúȯ Áß½ÉÀ¸·Î ƯȭµÈ ÇùÁø ÀÇ·á
¼­ºñ½º¸¦ Á¦°øÇÏ´Â ÀÇ¡¤ÇÑ ÇùÁø¼¾ÅÍ, ȯÀÚ ¼¼°è ÃÖ°í ¼öÁØÀÇ Áø·á½Ã½ºÅÛÀ» °®Ãá Àǰú
´ëÇк´¿ø, ÇÑÀÇÇÐÀ» ¼±µµÇÏ´Â ÇÑ¹æ ºê·£µåÆÄÀ§ 1À§ ÇÑÀǰú´ëÇк´¿ø¿Í Àü¹®¼º°ú ÆíÀǼºÀ» °®Ãá ȯÀÚ¸¸Á· º´¿øÀÎ Ä¡°ú´ëÇк´¿øÀÌ ÃÖ»óÀÇ ÀÇ·á¼­ºñ½º¸¦ Á¦°øÇϰí ÀÖ´Ù.

°­µ¿°æÈñ´ëÇб³º´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã °­µ¿±¸ µ¿³²·Î 892

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä